← Back
$ARQT All transactions

Arcutis Biotherapeutics, Inc.

A

$ Value

$0

Shares

20,568

Price

$0

Filed

Jun 16

Insider

Name

Heron Patrick J

Title

CIK

0001365617

Roles

Director 10% Owner

Transaction Details

Transaction Date

2025-06-12

Code

A

Table

Derivative

Ownership

Direct

Equity Swap

No

Shares After

20,568

Footnotes

Represents Restricted Stock Units ("RSUs") granted in connection with the Reporting Person's service as a non-employee director as of the Company's 2025 annual meeting of stockholders. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) RSU upon the vesting thereof, which shall occur on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date. Upon vesting of the RSUs, the settlement has been deferred by the Reporting Person, pursuant to the terms of the RSU Deferral Election Form adopted on October 23, 2024, maintained by the Company. | The shares reported herein are held of record by Frazier Life Sciences X, L.P. FHMLS X, L.P. is the general partner of Frazier Life Sciences X, L.P. and FHMLS X, L.L.C. is the general partner of FHMLS X, L.P. The Reporting Person is one of two managing members of FHMLS X, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. | The shares reported herein are held of record by Frazier Life Sciences VIII, L.P. FHM Life Sciences VIII, L.P. is the general partner of Frazier Life Sciences VIII, L.P. and FHM Life Sciences VIII, L.L.C. is the general partner of FHM Life Sciences VIII, L.P. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. | The shares reported herein are held of record by FHM Life Sciences VIII, L.L.C. The Reporting Person is one of two managing members of FHM Life Sciences VIII, L.L.C. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. | The shares are held directly by The Heron Living Trust 11/30/2004. The Reporting Person is the co-trustee of The Heron Living Trust 11/30/2004 and has voting and investment power of the securities held by The Heron Living Trust 11/30/2004. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. | The underlying shares subject to the option vest and become exercisable as to 100% on the earlier of the first anniversary of the grant date, June 12, 2025, or immediately before the next annual meeting of stockholders, subject to the continued service through the vesting date.

Filing Info

Accession No.

0002065881-25-000027

Form Type

4

Issuer CIK

0001787306

Heron Patrick J's History

Date Ticker Type Value
2026-01-23 MIRM J
2026-01-23 MIRM $9.0M
2025-09-26 MBX $12.0M
2025-06-23 HLVX A $0
2025-06-13 ARQT $35K
2025-06-12 ARQT A $0
2025-06-12 ARQT A $0
2025-06-05 ARQT $5K
2025-06-05 MBX A $0
2025-06-04 ARQT $25K

Other Insiders at ARQT (90d)

Insider Bought Sold Last
Leonard Keith R $997K 2026-03-02
Burnett Patrick
See Remarks
$505K 2026-03-02
Matsuda Masaru
See Remarks
$1.3M 2026-03-02
Welgus Howard G. $746K 2026-04-01
Watanabe Todd
See Remarks
$1.4M 2026-03-02
Edwards Larry Todd
See Remarks
$145K 2026-03-02
Vairavan Latha
SVP Chief Financial Officer
$106K 2026-03-02